NEW YORK, July 21, 2016 /PRNewswire/ --
Stock-Callers.com shifts investors' focus on the Biotech arena which is never without risks and controversies. Despite strong M&A activities, the overall industry sees a volatile market as costs and pricing pressures continue to persist. In today's pre-market research, we have uncovered the following stocks for further evaluation: EPIRUS Biopharmaceuticals Inc. (NASDAQ: EPRS), Ampio Pharmaceuticals Inc. (NYSE MKT: AMPE), Spark Therapeutics Inc. (NASDAQ: ONCE), and Lion Biotechnologies Inc. (NASDAQ: LBIO). Learn more about these stocks by accessing their free notes at:
Shares in Boston, Massachusetts headquartered EPIRUS Biopharmaceuticals Inc. ended Wednesday's session at $0.27, which was a slight decline of 0.04%. The stock recorded a trading volume of 1.15 million shares. The Company's shares are trading 52.93% below their 50-day moving average. Moreover, shares of EPIRUS Biopharmaceuticals, which develops, manufactures, and commercializes biosimilar therapeutics worldwide, have a Relative Strength Index (RSI) of 39.73.
Under the notes filed with the SEC on July 01st, 2016, EPIRUS Biopharmaceuticals closed the previously disclosed sale of all of the outstanding shares of its wholly owned subsidiary, EPIRUS Biopharmaceuticals, to Genefar B.V., for approximately $3.7 million in cash pursuant to the terms of a Stock Purchase Agreement. Free notes on EPRS are available at:
Englewood, Colorado headquartered Ampio Pharmaceuticals Inc.'s stock rose 2.31%, closing the day at $0.97 with a total volume of 403,178 shares traded. Shares of the Company, which focuses on developing therapies for the treatment of prevalent inflammatory conditions in the U.S., are trading 67.24% below their 200-day moving average. The stock has an RSI of 18.18.
On June 30th, 2016, Ampio Pharmaceuticals announced the results of the Ampion™ PIVOT clinical trial as well as a comprehensive analysis that integrates trial data from three single injection studies that will be presented to the FDA. The complimentary notes on AMPE can be accessed at:
On Wednesday, Philadelphia, Pennsylvania headquartered Spark Therapeutics Inc.'s stock recorded a trading volume of 290,050 shares and ended the day 3.78% higher at $54.43. The Company's shares have advanced 17.69% in the past month, 44.26% in the previous three months, and 20.13% since the start of this year. The stock is trading above its 50-day and 200-day moving averages by 10.58% and 26.39%, respectively. Furthermore, shares of Spark Therapeutics, which focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases, have an RSI of 57.69.
On July 01st, 2016, Spark Therapeutics announced the publication in The Lancet of long-term data from a Phase 1 trial of voretigene neparvovec (SPK-RPE65), its most advanced product candidate which has received breakthrough therapy and orphan product designation for the treatment of inherited retinal disease caused by mutations in the RPE65 gene. The publication is the first to report full cohort results of injection of the second eye with an AAV vector, and demonstrated the overall safety of the approach. In addition, the data showed long-term stable and persistent benefit for at least 3 years, with observation ongoing, in retinal and visual function and functional vision after voretigene neparvovec injection.
On July 12th, 2016, research firm RBC Capital Markets initiated an 'Outperform' rating, issuing a target price of $70 on the Company's stock. Visit us today and access our complete notes on ONCE at:
New York-based Lion Biotechnologies Inc.'s stock jumped 5.40%, finishing yesterday's session at $8.20 and with a total volume of 221,392 shares traded. The Company's shares have advanced 2.37% in the last one month, 42.86% over the previous three months, and 6.22% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 15.11% and 28.72%, respectively. Additionally, shares of Lion Biotechnologies, which focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells, have an RSI of 55.94.
On June 08th, 2016, Lion Biotechnologies announced the closing of its previously announced private financing with institutional and other accredited investors. Lion Biotechnologies received gross proceeds of $100 million, before paying the placement agents' fees and estimated offering expenses payable by the Company. At the closing, the Company issued 9,684,000 shares of common stock and 11,368,633 shares of its new non-voting Series B Preferred Stock. The proceeds will be used to further advance the Company's clinical program in utilizing tumor infiltrating lymphocytes immunotherapy in treating solid tumors. Get free access to your notes on LBIO at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: [email protected]
Phone number: +44 330 808 3765
Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA